PerkinElmer (PKI) Acquires BioLegend for $5.25B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
PerkinElmer to Acquire Antibody and Reagent Leader BioLegend
July 26, 2021 6:30 AM EDTTransformative deal significantly scales leading position in life science to accelerate legendary discoveries in precision medicine
Leader in antibody development with highly complementary, innovative portfolio in emerging, high-growth areas of biologics, cell and gene therapy, proteogenomics, and recombinant proteins Commercial synergy opportunity to accelerate life science growth with potential benefits for diagnostics franchise Annual BioLegend revenues of approximately $380 million estimated in 2022 with mid-teens-plus expected revenue growth (excluding synergies) Elevated growth and margin profile for combined company with strong, immediate adjusted earnings per share... More